Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease

Nephron

Volumn 129, Issue 1, 2015, Pages 29-33

  Lin, Joseph H ^a   Zhang, Jenny J ^a   Lin, Shao Lee ^a   Chertow, Glenn M ^b  

^a GILEAD SCIENCES   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACEi; Albuminuria; ARB; ASK1; Diabetic kidney disease; DKD; EGFR; GS 4997; Phase 2; Proteinuria

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; PLACEBO; SELONSERTIB; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOPTOSIS SIGNAL REGULATING KINASE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MAP3K5 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; STUDY DESIGN; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MAP KINASE KINASE KINASE 5; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS;

EID: 84940944661     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000369152     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention: National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA 2011, pp 1-12.
2. de Boer IH, Rue TC, Hall Y.N., Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305:2532-2539.
3. El Nahas AM, Muchaneta-Kubara EC, Essawy M., Soylemezoglu O: Renal fibrosis: insights into pathogenesis and treatment. Int J Biochem Cell Biol 1997; 29:55-62.
4. Karamouzis I, Sarafidis PA, Karamouzis M, Iliadis S., Haidich AB, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM: Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 2008; 28:397-404.
5. Dounousi E, Papavasiliou E, Makedou A., Ioannou K, Katopodis KP, Tselepis A, Siamopoulos K.C., Tsakiris D: Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48:752-760.
6. Hinokio Y, Suzuki S, Hirai M., Suzuki C, Suzuki M, Toyota T: Urinary excretion of 8-oxo-7, 8-dihydro-2'-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 2002; 45:877-882.
7. Ray PD, Huang BW, Tsuji Y: Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012; 24: 981-990.
8. Nagai H, Noguchi T, Takeda K., Ichijo H: Pathophysiological roles of ASK1-MAP kinase signaling pathways. J Biochem Mol Biol 2007; 40:1-6.
9. Soga M, Matsuzawa A, Ichijo H: Oxidative stress-induced diseases via the ASK1 signaling pathway. Int J Cell Biol 2012; 2012:439587.
10. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C., Dowling J, Atkins RC, Tesch GH: Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 2004; 47: 1210-1222.
11. De Borst MH, Prakash J, Melenhorst W.B., van den Heuvel MC, Kok RJ, Navis G, van Goor H: Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. J Pathol 2007; 213:219-228.
12. Sakai N, Wada T, Furuichi K., Iwata Y, Yoshimoto K, Kitagawa K, Kokubo S., Kobayashi M, Hara A, Yamahana J, Okumura T, Takasawa K, Takeda S, Yoshimura M, Kida H, Yokoyama H: Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis 2005; 45:54-65.
13. Tobiume K, Matsuzawa A, Takahashi T., Nishitoh H, Morita K, Takeda K., Minowa O, Miyazono K, Noda T, Ichijo H: ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2001; 2:222-228.
14. Saitoh M, Nishitoh H, Fujii M., Takeda K, Tobiume K, Sawada Y., Kawabata M, Miyazono K, Ichijo H: Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17:2596-2606.
15. Bunkoczi G, Salah E, Filippakopoulos P., Fedorov O, Muller S, Sobott F., Parker SA, Zhang H, Min W, Turk BE, Knapp S: Structural and functional characterization of the human protein kinase ASK1. Structure 2007; 15: 1215-1226.
16. Liles JT, Yang H, Fogo A.B., Breckenridge DG: A Small Molecule Inhibitor of Apoptosis Signalregulating Kinase 1 (ASK1) reduces Key Pathological Processes Related to CKD. American Society of Nephrology Annual Conference Asbtracts, 2014, Asbtract 5028.
17. Karnik S, Charlton M, Popov Y., Nash M, Barry V, Huntzicker E., French D, Li K, Decaris M, Emson C, Turner S, Goodman Z, Breckenridge D, Tumas D: Pharmacological inhibition of apoptosis signal-regulating kinase 1 (ASK1) in a murine model of NASH with preexisting disease blocks fibrosis, steatosis, and insulin resistance. American Association for the Study of Liver Disease, The Liver Meeting 2014, Asbtract 2028810.
18. Babazono T, Nyumura I, Toya K., Hayashi T, Ohta M, Suzuki K., Kiuchi Y, Iwamoto Y: Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care 2009; 32:1518-1520.
19. Levey AS, Inker LA, Matsushita K, Greene T., Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J: GFR Decline as an Endpoint for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014, in press.
20. House AA, Eliasziw M, Cattran D.C., Churchill DN, Oliver MJ, Fine A, Dresser G.K., Spence JD: Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010; 303:1603-1609.
21. Mann JF, Green D, Jamerson K., Ruilope LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527-535.
22. Tuttle KR, Bakris GL, Toto R.D., McGill JB, Hu K, Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28:2686-2690.
23. Evans M, Bain SC, Hogan S, Bilous RW: Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Nephrol Dial Transplant 2012; 27:2255-2263.
24. Altemtam N, Russell J, El Nahas M: A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant 2012; 27:1847-1854.